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Preface 
Earlier diagnosis and treatment, plus biological therapies, have 
transformed the outlook for many patients with rheumatoid arthritis.  In 
the future new biomarkers for diagnosis, prognosis and therapeutic 
response will further improve outcomes.  Additionally, pre-clinical 
diagnosis and tolerogenic therapies could provide sustained remission for 
some individuals, although ethical and societal challenges must also be 
addressed before rheumatoid arthritis becomes ‘yesterday’s disease’. 
 
Introduction 
Rheumatoid arthritis affects 580,000 people in the United Kingdom, with a 
further 26,000 people developing the disease annually 1.  Similar 
prevalence and incidence figures apply to most developed countries.  Over 
the past decade, new treatment paradigms and therapeutic approaches 
have transformed the disease from a chronic, disabling condition, 
frequently requiring palliative measures, to a potentially curable illness 
wherein sufferers retain their independence, quality of life and 
contribution to society 2.  However, despite this dramatic turnaround in 
outlook , several scientific, societal and ethical issues must be resolved 
before rheumatoid arthritis becomes a disease of the past.  These 
encompass the need for early recognition, the ability to provide a firm 
diagnosis and prognosis in the earliest disease stages and the ability to 
optimise treatment for the individual patient.   
In this article, I review the changing face of rheumatoid arthritis 
treatment, the need for biomarkers to guide ever earlier diagnosis and 
treatment and attempt to predict the future approaches for the 
management of rheumatoid arthritis. My main focus is the societal 
implications of these changes, rather than the underpinning science, 
which has recently been reviewed elsewhere.3 
 
The consequences of rheumatoid arthritis  
Rheumatoid arthritis is a chronic inflammatory disease of the synovium, a 
delicate membrane that lines the non-weight bearing surfaces of the joint 
4.  In rheumatoid arthritis, the synovium becomes infiltrated with chronic 
inflammatory cells (Figure 1).  The resident fibroblasts adopt a ‘quasi-
malignant’ phenotype with up-regulation of oncogenes, inhibition of 
apoptosis and secretion of cytokines, chemokines and enzymes that 
reinforce the inflammation and catalyse joint destruction.  The resulting 
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‘pannus’ acquires the ability to invade and destroy adjacent articular 
cartilage 5.  Activation of osteoclasts in peri-articular bone leads to 
resorption and ‘erosions’, a radiological hallmark of the disease 6.  Similar 
processes affect the synovium lining tendon sheaths resulting in tendon 
weakness and rupture, responsible for the characteristic deformities of 
rheumatoid arthritis.  Rheumatoid arthritis can also involve organs such as 
the lung, leading to inflammation and fibrosis, and the systemic effects of 
rheumatoid arthritis include osteoporosis, anaemia, and profound fatigue.  
Serious collateral damage takes the form of premature atherosclerosis, 
which accounts for the reduced lifespan of patients with severe 
rheumatoid arthritis as a consequence of heart attacks and strokes 7. 
 
Up to a third of patients with rheumatoid arthritis stop working within 2 
years of disease onset as a consequence of these dramatic changes 8.  
Reduced physical function initially reflects joint inflammation itself but, 
beyond the first few years, physical impairment correlates more closely 
with joint damage.  Because damage is irreversible, functional loss is 
permanent and associated with a significantly reduced quality of life.  In 
addition to heart attacks and strokes, rheumatoid arthritis patients also 
suffer frequent infections, a consequence of both the disease itself and the 
drugs used to treat it.  Other iatrogenic complications include peptic ulcer 
disease, bone marrow suppression and liver damage.  In short, 
rheumatoid arthritis is a devastating disease that affects the whole 
individual, reducing their contribution to society, destroying their quality 
of life and shortening their lifespan.  In the UK, the estimated costs of 
rheumatoid arthritis include £560 million a year in healthcare costs plus 
£1.8 billion in sick leave and work-related disability 1. Until the disease is 
eradicated, there will remain a very significant unmet personal and 
societal need. 
 
 Heterogeneity and biomarkers 
[Au: To fit the page layout the main headings must be 33 
characters max (including spaces)] 
Few clinically useful biomarkers exist for rheumatoid arthritis in terms of 
diagnosis, prognosis or treatment response (Box 1).  It is a polygenic 
disease, probably with various environmental triggers 9 (Figure 2).  
Symptoms can develop at different rates and in different joints, from 16 
years of age to old age.  There are also several disease mimics, 
particularly post-infectious syndromes such as reactive arthritis but also 
other chronic joint diseases with a lesser propensity to cause rapid 
damage.  The discovery of antibodies against citrullinated peptide 
antigens (anti-citrullinated peptide antibodies (ACPA)) has improved 
diagnostic accuracy for ‘seropositive’ rheumatoid arthritis patients (about 
two thirds of patients carry this autoantibody) but a significant proportion 
of patients who eventually develop rheumatoid arthritis cannot be 
diagnosed at symptom onset 10.  These individuals carry the label 
‘undifferentiated arthritis’ until further disease progression allows them to 
be distinguished from other types of inflammatory arthritis.   
 
Among patients with definite early rheumatoid arthritis there is a 
spectrum of disease outcomes, ranging from relatively benign disease to 
aggressive disease, in which x-ray damage appears within months of 
diagnosis.  Autoantibodies, particularly ACPA, tend to associate with more 
aggressive disease but this is by no means inevitable, and other 
prognostic markers are similarly non-specific.  Consequently most patients 
cannot be given an accurate prognosis at disease onset with respect to 
ultimate joint damage. 
 
Currently we cannot predict which patients will respond well to particular 
anti-rheumatic therapies.  Therefore, each patient is managed according 
to a predetermined treatment algorithm until inflammation is adequately 
controlled (see below).  Even with modern treatment approaches some 
patients will experience significant delay until their disease is brought 
under optimal control, when first-line drugs fail to provide relief.   
 
The changing face of treatment 
The traditional management of rheumatoid arthritis adopted the so-called 
pyramid approach.  Initial symptoms were managed with non-steroidal 
anti-inflammatory drugs (NSAIDs), which relieved symptoms but did not 
prevent cartilage and bone damage.  Damage on x-rays triggered the 
prescription of disease-modifying anti-rheumatic drugs (DMARDs), such as 
gold, penicillamine, hydroxychloroquine, sulphasalazine and methotrexate.  
To a greater or lesser degree these retarded (but didn’t prevent) joint 
damage.  A characteristic feature of rheumatoid arthritis is that even 
highly effective drugs tend to lose their benefit with time, and a 
succession of DMARDs would be prescribed until there were none left to 
try.  The third and final tier of treatment involved cytotoxic chemotherapy 
with drugs such as azathioprine and cyclophosphamide, or experimental 
approaches such as thoracic duct drainage.  Glucocorticoids were the 
mainstay of treatment in long-standing rheumatoid arthritis, although 
their potent anti-inflammatory benefits were counterbalanced by 
numerous metabolic and immunosuppressive side effects 11. 
 
During the 1980s and 1990s, with the recognition that joint damage was 
irreversible, DMARDs (usually sulphasalazine or methotrexate) were 
prescribed earlier in disease 12.  Failure of a DMARD signalled its 
replacement, or addition (‘step-up’ combination therapy) of an alternative 
drug. However, several trials demonstrated that effective inflammation 
control during early rheumatoid arthritis minimised subsequent joint 
damage and destruction, apparently transforming the disease to a milder 
phenotype.  Because DMARDs take many weeks to work and the response 
of the patient is unpredictable, this ‘window of opportunity’ led to the use 
of ‘step-down’ therapy.  To avoid missing the ‘window’, multiple drugs 
were initiated at diagnosis, including temporary glucocorticoids 13-15.  Once 
inflammation was suppressed, drug doses could be tapered.   
The development of disease activity measures, such as the disease 
activity score utilising 28 joints (DAS28), has resulted in modified 
strategies whereby treatment is adjusted to maintain a target level of 
disease activity, usually remission or low disease activity (treatment-to-
target strategies)16.  Trials of different strategies have confirmed that 
initial combination therapy controls disease more rapidly with reduced x-
ray damage in the medium term.  Physical function is well preserved in 
the short-term, regardless of the exact strategy adopted, however, 
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emphasising the overarching importance of tight disease control in 
optimising outcomes [Au: OK?] 17, 18.   
 
The development of biological therapies heralded one of the most 
dramatic changes in outlook for patients with established rheumatoid 
arthritis.  New pathogenic insights, alongside the monoclonal antibody 
revolution, led to the licensing of a succession of biological therapies that 
target specific aspects of the disease process.  Following the advent of 
tumour necrosis factor (TNF) blockade in the early 1990s, B-cell depletion, 
co-stimulation blockade and interleukin-6 receptor blockade have each 
offered new, ‘targeted’ approaches to therapy (Box 2). These drugs 
effectively control the symptoms and signs [au: what exactly do you 
mean by signs? Isn’t this the same as symptoms?] of rheumatoid 
arthritis, even in patients with relatively advanced disease.  Of major 
significance, they substantially retard and frequently halt joint damage. 
Nonetheless, up to 50% of patients with established rheumatoid arthritis 
do not respond to these drugs, and only a relatively small proportion 
achieve complete remission of disease activity 19.  
 
Initially biological therapies were reserved for patients who had failed all 
conventional DMARDS, but their potency and particularly their ability to 
arrest joint damage led to trials in early rheumatoid arthritis with 
remission rates as high as 50% 20.  However, these drugs are orders of 
magnitude more expensive than conventional DMARDs and their side 
effect profiles include serious and opportunistic infections. Furthermore, 
Comment [n1]: I prefer the original – 
because the emphasis is that tight disease 
control is the most important thing to get 
right regardless of the exact strategy 
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altogether is space precludes it. 
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around 30% of patients with early rheumatoid arthritis achieve low 
disease activity with methotrexate alone 21, 22. 
 
Early biologics for all? 
Until clinically useful biomarkers of diagnosis, prognosis and therapeutic 
response are identified, some rheumatoid arthritis patients will accrue 
early joint damage and downstream disability.  Recent studies have 
attempted to determine the ‘disability-equivalent’ of a ‘quantum’ of x-ray 
damage and suggest that all damage matters 23.  Furthermore, several 
studies suggest that, for a given level of disease activity, more damage 
will accrue with traditional DMARDs than with biological therapy 24. 
 
This has strengthened calls for the use of biological therapies in patients 
with early rheumatoid arthritis.  Studies of such strategies indicate that a 
proportion of patients can discontinue the biological therapy within a year 
or two, maintaining disease remission on traditional DMARDs or perhaps 
not requiring further treatment at all 25.  Counterarguments focus on the 
costs of such an approach and the fact that a proportion of patients will be 
over-treated and exposed unnecessarily to the side effects of biological 
drugs.   
 
Control of rheumatoid arthritis in its early stages is associated with long-
term financial savings, in terms of future drug therapy and a reduced 
need for in-patient rehabilitation and orthopaedic surgery on damaged 
joints 26.  Continued employment also can offset the up-front costs, 
depending on the type of economic modelling used 27.  Furthermore, 
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patients with well-controlled rheumatoid arthritis suffer fewer infections 
than those with active disease, potentially offsetting the risks associated 
with the early use of biological therapies.  In addition, rapid and effective 
control of inflammation should minimise the incidence of premature heart 
disease and stroke, with additional significant cost savings.  Therefore, the 
universal use of step-down biological therapy in early rheumatoid arthritis 
has several attractive features but remains highly controversial. 
 
‘Pre rheumatoid arthritis’  
It has been shown repeatedly that the time to first treatment influences 
the ultimate outcome for patients with rheumatoid arthritis.  In line with 
the ‘window of opportunity’, patients who present to a rheumatologist and 
receive treatment within weeks of symptom onset have better long-term 
outcomes than those that experience treatment delay 28.  Furthermore, 
studies are now starting to address whether the treatment of 
undifferentiated arthritis prevents, or delays the progression to, 
rheumatoid arthritis.  For example, administration of methotrexate to 
patients with undifferentiated arthritis OK? delayed progression to 
rheumatoid arthritis, at least in those who carried ACPA, and the 
developing disease appeared less aggressive in those individuals 29.  Co-
stimulation blockade also reduced autoantibody titres and, possibly, 
radiographical damage at this stage of disease 30.  In type 1 diabetes, a 
related autoimmune disease, administration of CD3-specific monoclonal 
antibody therapy at disease onset has been shown to delay progression of 
disease for at least 18 months, with many patients remaining effectively 
insulin independent during this time 31.  Such approaches could re-induce 
Comment [n3]: Yes, ok 
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self-tolerance to autoantigen, switching off the disease process and 
offering a potential cure 32. 
 
The delay to treatment has a profound effect on the burden of rheumatoid 
arthritis to both the individual and society.  At present in the UK, 
approximately 10% of patients with rheumatoid arthritis commence 
treatment within 3 months of symptom onset.  Doubling that proportion to 
20% should become cost-neutral to the UK National Health Service (NHS) 
after 9 years, in addition to significant productivity gains for the economy 
1.  The factors responsible for treatment delay (the current median time is 
9 months from first symptoms) reflect either patient delay in reporting 
symptoms to their GP, or GP delay in referral to secondary care 33.  In the 
UK, the second of these is being effectively addressed by appropriate GP 
education and rapid-access early arthritis clinics, and it is now the patient 
delay that most threatens an optimal outcome 34.  A public awareness 
campaign may address this but, because musculoskeletal pain is so 
ubiquitous and the presentation of rheumatoid arthritis so variable, the 
message must be carefully worded.  In the US, the balance between 
patient and GP/internist delay varies by Centre and geographical location 
but managed care regulations may also discourage referral to a 
rheumatologist, potentially delaying treatment.  [Au: OK?] 
 
Serum samples from individuals who ultimately develop rheumatoid 
arthritis clearly show that immune tolerance may be broken many years 
before clinical disease presentation.  Thus, autoantibodies may be present 
in blood samples collected ten years or more prior to diagnosis, with a 
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subsequent rise in the expression levels of C-reactive protein and other 
pro-inflammatory mediators 35-39.  Arthroscopic studies have also 
demonstrated synovitis in clinically ‘silent’ joints at disease presentation 
40.  So, even encouraging individuals to report early symptoms may miss 
the critical time period [Au: for clarity, it might be worth specific 
exactly when the critical time period (at disease onset?)] for 
restoring immune tolerance, which may be during the asymptomatic, pre-
clinical disease stage. 
 
If it were possible to identify individuals with ‘pre-rheumatoid arthritis’, 
several exciting possibilities would ensue.  These include simple measures 
such as lifestyle advice, incorporating smoking cessation and healthy 
eating, although there is currently no evidence that modifying these 
rheumatoid arthritis risk factors would protect from disease development. 
41.  Very early intervention with DMARDs or biological therapies 
recapitulates earlier arguments around early rheumatoid arthritis but, in 
preclinical disease, milder drugs could be effective.  Recently, a brief 
intervention with glucocorticoids was shown to reduce autoantibody levels 
but did not inhibit progression to rheumatoid arthritis 42.  A particularly 
attractive option might be approaches such as the induction of mucosal 
tolerance using a mixture of joint antigens; although thus far not effective 
in established rheumatoid arthritis, this is potentially a safe and effective 
way to stop the developing disease in its tracks, 43, 44. 
 
Because the heritability of rheumatoid arthritis is less than that of type 1 
diabetes, screening family members would identify just a small proportion 
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of those in the earliest disease stages.  Population screening for ACPA 
would identify a proportion of those destined to develop seropositive 
rheumatoid arthritis but miss seronegative disease, and those in whom 
autoantibodies develop later 45.  Genetic screening for polymorphisms 
strongly associated with rheumatoid arthritis such as HLA-DRΒ1 shared 
epitope alleles, and the C1858T single nucleotide polymorphism in protein 
tyrosine phosphatase, non-receptor type 22 (PTPN22) could be 
incorporated into a ‘risk equation’ along with serological and demographic 
factors.  However, such an approach would require robust validation, as 
well as substantial debate around the associated ethical issues.  The 
accuracy would not be 100%, but the potential risk identified would be 
life-long, providing a cohort of at-risk but healthy individuals.  
Furthermore even therapies that appear safe, such as mucosal tolerance 
induction, may not be risk-free.  The lack of in vitro models of rheumatoid 
arthritis immunopathology that enable risk prediction, or of animal models 
that provide an accurate risk assessment for human therapy are limiting 
in this regard, and therefore the optimal way forward may not be obvious 
46. 
 
Imaging rheumatoid arthritis 
New imaging approaches are providing novel insights into rheumatoid 
arthritis pathogenesis, while also providing a window to early and pre-
clinical disease.  Similar to arthroscopy, ultrasound and magnetic 
resonance imaging (MRI) in early rheumatoid arthritis often reveals sub-
clinical inflammation in apparently unaffected joints and may also provide 
sensitive prognostic indicators 47-51.  MRI is expensive and requires 
significant infrastructure, but musculoskeletal ultrasound (MSUS) is 
becoming widely adopted by rheumatologists as a routine adjunct to 
clinical examination.  In early arthritis clinics, MSUS provides a useful 
diagnostic aid and could provide a means of screening individuals at high 
risk of developing rheumatoid arthritis, perhaps annually.  In this way, 
intervention could be targeted at patients with objective, albeit 
asymptomatic, evidence of early inflammatory joint disease. 
 
The future patient pathway  
So how might rheumatoid arthritis management look in the future (Figure 
3)?  Recent-onset joint symptoms and objective synovitis should trigger a 
screen for diagnostic, prognostic and treatment-response biomarkers.  
These parameters, along with imaging findings, will inform the most 
appropriate treatment plan.  Patients with good prognosis rheumatoid 
arthritis and appropriate treatment response biomarkers may receive 
methotrexate and expect an excellent outcome.  Others may require 
immediate biological therapy.  In most patients, the symptoms will come 
under rapid control, at which stage additional biomarkers may inform the 
decision of whether treatment could be tapered or stopped altogether.  
Currently, about 40% of patients in remission experience disease flare 
after therapy withdrawal but biomarkers of true disease remission versus 
drug-induced disease suppression should facilitate targeted therapy 
reduction 52, 53.  
 
Population screening may allow the identification of individuals at high risk 
of developing rheumatoid arthritis.  After appropriate counselling, such 
individuals could be offered lifestyle advice and perhaps specific therapies, 
including mucosal tolerance approaches, with the hope of permanent 
disease remission. [Au: is this not a bit strong? Perhaps ‘with the 
hope of permanent disease remission’ is more accurate??]  
Alternatively, such patients may undergo further annual screening with 
imaging.  The identification of synovitis could then trigger prescription of 
drugs such as hydroxychloroquine, or a brief course of glucocorticoids, in 
an attempt to delay or prevent progression to rheumatoid arthritis 54, 55.  
Clearly this area is ripe for research and these suggestions are highly 
speculative.   
 
Compared to current management, economic resource will be invested in 
the early and pre-clinical stages of rheumatoid arthritis, including 
screening strategies and biomarkers, and away from palliative measures, 
including joint surgery.  Our target for rheumatoid arthritis patients should 
be ‘normal health’ and the development of disability a signal of 
management failure. To achieve this, early and aggressive remission-
inducing treatment, potentially incorporating tolerance inducing 
strategies, will become the norm.  Earlier in this article I referred to the 
‘quasi-malignant’ phenotype of rheumatoid arthritis.  Our quest for 
managing earlier disease, and our evolving treatment strategies utilising 
drug combinations, now have strong parallels with oncological treatment 
paradigms. 
 
Conclusions 
Rheumatoid arthritis provides a model for potentially reversible 
autoimmunity [Au: OK?] which, inadequately treated, causes joint 
damage, long term disability, impaired quality of life, reduced lifespan and 
a large societal burden.  Over the past twenty years earlier treatment and 
the use of biological therapies has greatly improved patient outlook but 
there still remains a large unmet patient need.  Still earlier treatment will 
make a significant difference.  However, scientific advances in terms of 
biomarker evaluation and preclinical disease identification could lead to a 
step change in prognosis.  There also remain several fascinating questions 
around rheumatoid arthritis pathogenesis, the answers to which could also 
improve outcomes (Box 3).   
 
 
Box 1. Current rheumatoid arthritis biomarkers and gaps in knowledge. 
Diagnostic biomarkers 
• anti-CCP 
• rheumatoid factor 
Gaps:  
Biomarkers needed for ‘seronegative’ RA 
 
 
Prognostic biomarkers 
• serological: ACPA, rheumatoid factor 
• genetic: shared epitope (related to ACPA generation), 
sulphoxidation status56 
• radiological: joint damage due to RA at first presentation 
• other: high CRP at presentation 
Gaps:  
Lack of sensitivity and specificity. 
 
  
Therapeutic biomarkers  
• autoantibodies: seropositive patients may be more likely to 
respond to rituximab and less likely to respond to TNFα blockade 
(ref – manuscript under review) 
• other potential biomarkers (transcriptional profiles, synovial 
biomarkers, multi protein arrays) have been studied in relatively 
small patient numbers 
Comment [n5]: I prefer immuno-
inflammation because, in established 
disease, autoimmunity may be less relevant 
– there is now uncontrolled chronic 
inflammation.  I haven’t really emphasised 
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Gaps:  
None are validated or replicated.  
Most associate with degree of response rather than response vs lack of 
response, eg at present there are no predictors for primary non-response 
to anti-TNF.   
Synovial biomarkers of mechanistic interest but currently unlikely to be 
broadly useful clinically because few units perform synovial biopsy 
 
 
Remission biomarkers 
• Lack of synovitis on imaging (MSUS, MRI). 
Limitations:   
Requires infrastructure.   
Does not correlate with ability to stop therapy without precipitating flare  
 
 
Tolerance biomarkers 
• None identified in autoimmune disease.   
Gaps 
Essential to develop/monitor tolerogenic therapies 
May also be useful for monitoring disease tapering for patients in 
remission 
 
Box 2.  Current biological therapies for rheumatoid arthritis  
TNF antagonists: 
infliximab 
 chimeric monoclonal antibody 
 neutralises TNFα 
 binds soluble and cell surface TNFα 
 administered by intravenous infusion every 8 weeks following 
loading doses 
  
etanercept 
 recombinant dimeric fusion protein of p75 TNF receptor and hinge, 
CH2 and CH3 of human IgG1 
 neutralises TNFα 
 binds cell surface TNFα with lower affinity than monoclonal 
antibodies 
 administered by weekly subcutaneous injection 
  
adalimumab 
 fully human monoclonal antibody  
 neutralises TNFα 
 binds soluble and cell surface TNFα 
 administered by subcutaneous injection every other week 
  
golimumab 
 fully human monoclonal antibody  
 neutralises TNFα 
 binds soluble and cell surface TNFα 
 administered by monthly subcutaneous injection 
  
certolizumab pegol 
 PEGylated humanised FAB fragment. No Fc. 
 neutralises TNFα 
 binds soluble and cell surface TNFα 
 administered by subcutaneous injection every other week following 
loading dose 
  
  
Anti-B cell therapy  
Rituximab 
 Chimaeric monoclonal antibody  
 Binds to CD20 and lyses CD20-expressing target cells 
 Administered as a course of 2 intravenous infusions, which can be 
repeated according to disease activity (usually approximately every 6 
months) 
  
 
Costimulation blockade 
Abatacept 
 Fusion protein between the extracellular domain of CTLA4 and a 
modified hinge, CH2 and CH3 of human IgG1 
 Binds CD80 and CD86 in competition with CD28, inhibiting T-cell 
activation (costimulation blockade) 
 Administered by monthly intravenous infusion after loading doses 
  
 
Anti-IL6 receptor therapy 
Tocilizumab 
 Humanised monoclonal antibody 
 Binds soluble and cell surface bound IL6 receptor, inhibiting IL-6 
signalling 
 Administered by monthly intravenous infusion 
Box 3. Unanswered aetiopathogenic questions in rheumatoid arthritis  
Areas of current and future research with potential therapeutic impact 
 
Improved markers of ‘pre-RA’ – early identification of ‘at risk’ individuals, 
enabling ‘preventative’ studies 
Window of opportunity – what is/are the pathological correlates? 
Therapeutic ‘escape’ – what underlies loss of therapeutic response. 
?similar to tumour ‘escape’ in malignancy  
Methotrexate – identification of mode of action and efficacy biomarkers, to 
optimise therapy with this ‘anchor’ drug and develop related compounds 
Biomarkers of diagnosis to enable rapid diagnosis 
Biomarkers of prognosis to assist targeted treatment 
Biomarkers of therapeutic response to optimise choice of therapy 
Biomarkers of true remission (imaging and blood) to assist with therapy 
tapering  
Biomarkers of tolerance induction to inform withdrawal of therapy 
 
Figure Legends 
Figure 1. The Pathology of rheumatoid arthritis.  In rheumatoid arthritis, 
the synovial membrane becomes infiltrated with a wide variety of 
inflammatory cell types, which synergise to cause joint destruction.  T 
cells are clearly important, as evidenced by the genes associated with 
rheumatoid arthritis (see Figure 2) [Au: associations of RA with what? 
Please specify] 57.  In particular, TH17 cells may orchestrate synovitis 
and damage via interactions with dendritic cells, macrophages and B cells 
58.  By contrast, the function of regulatory T cells appears to be impaired 
in rheumatoid arthritis [Au: OK?] 59.  Macrophages are also key players 
and their presence correlates with symptoms, perhaps via secretion of 
critical inflammatory mediators 60.  The success of B cell-specific antibody 
therapy attests to the importance of B cells in rheumatoid arthritis 
pathogenesis.  In addition to autoantibody secretion, B cells present 
antigen to T cells and stimulate synovial fibroblasts via secretion of 
cytokines such as lymphotoxin-β (LTβ) and tumour necrosis factor (TNF).  
In some patients, well-formed lymphoid follicles are present in the 
synovium, suggestive of local antigen presentation, whereas in other 
patients B cells are present in aggregates and scattered more diffusely61. 
Synovial fibroblasts are key players in joint damage via the secretion of 
matrix metalloproteinases and cathepsins.  Initially, they are activated by 
the inflammatory micro-environment but subsequently take on a semi-
autonomous, ‘quasi-malignant’ phenotype 62.  Bone damage is caused by 
the convergence of multiple signals upon osteoclast precursors in the 
subchondral bone, inducing their differentiation and maturation 63.  
Comment [n6]: Omit joints 
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Important cells that are omitted from this Figure include synovial mast 
cells and plasma cells.   
 
Figure 2 – The aetiology of rheumatoid arthritis and timelines of disease 
onset. 
Several genetic susceptibility loci have now been associated with 
rheumatoid arthritis 57. HLADRB1 remains the strongest but other genes 
are associated with several different autoimmune diseases.  Some of 
these (such as PTPN22 and CTLA4) are immunoregulatory, emphasising a 
primary disruption of immune regulation in families with autoimmunity.  
Cigarette smoking is strongly associated with seropositive (but not 
seronegative) rheumatoid arthritis.  Several studies support a gene–
environment interaction whereby smoking triggers the production of ACPA 
in individuals who carry the ‘shared epitope’ (A)64.  Evidence associating 
caffeine consumption and obesity with rheumatoid arthritis is less 
consistent 41.  A ‘Mediterranean’ diet and diets rich in fruit and vegetables 
appear to protect against rheumatoid arthritis, possibly via a beneficial 
effect of olive and fish oils, and anti-oxidants, respectively.  Alcohol may 
also protect 65, whereas evidence for a protective effect of oestrogens is 
inconsistent.   
Retrospective studies demonstrate the presence of rheumatoid factor 
and/or ACPA for up to 15 years before clinical rheumatoid arthritis (B).  
Levels of acute phase proteins, cytokines and chemokines start to rise 
during the final few years before the disease presents (D).  The trigger(s) 
for this period of gradually increasing inflammation that culminates in 
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clinical rheumatoid arthritis has not been identified but, anecdotally, 
patients report infections, trauma and stress as preceding factors (C). 
At disease presentation, joint imaging will demonstrate inflammation in 
joints that are not yet symptomatic (E). 
 
Figure 3. The future rheumatoid arthritis patient pathway. 
Individuals presenting with joint pain will undergo joint imaging and will 
be tested for a range of biomarkers (column 2).  If rheumatoid arthritis is 
confirmed they will receive biomarker-guided treatment, to ensure rapid 
and safe efficacy.  Management will follow ‘treatment-to-target’ principles, 
aiming for disease remission (see text).  Imaging may be used to confirm 
the lack of synovitis.  At this stage, further biomarkers will guide the 
tapering of therapy, to avoid subsequent disease flares during the 
attainment of ‘drug-free remission’ in some patients. 
Individuals with a strong family history of rheumatoid arthritis, or in 
whom screening has revealed a strong genetic predisposition with or 
without ACPA may choose to modify their lifestyles (column 1).  They may 
also choose to receive a ‘tolerogenic’ intervention such as mucosal 
exposure to collagen or other joint autoantigens.  Such therapy may be 
monitored using biomarkers of tolerance induction and followed by annual 
imaging.   
Others may simply choose to undergo annual imaging of hands and feet 
(the most common target joints for rheumatoid arthritis).  If such 
screening reveals early synovitis then they will follow the synovitis 
pathway outlined above (path A). 
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Box 1: RA biomarkers 
 
Diagnostic biomarkers 
• anti-CCP 
• rheumatoid factor 
Gaps:  
Biomarkers needed for ‘seronegative’ RA 
 
 
Prognostic biomarkers 
• serological: ACPA, rheumatoid factor 
• genetic: shared epitope (related to ACPA generation), 
sulphoxidation status 
• radiological: joint damage due to RA at first presentation 
• other: high CRP at presentation 
Gaps:  
Lack of sensitivity and specificity. 
 
  
Therapeutic biomarkers  
• autoantibodies: seropositive patients may be more likely to 
respond to rituximab and less likely to respond to TNFα blockade 
(ref – soon to be submitted review) 
• other potential biomarkers (transcriptional profiles, synovial 
biomarkers, multi protein arrays) have been studied in relatively 
small patient numbers 
Gaps:  
None are validated or replicated.  
Most associate with degree of response rather than response vs lack of 
response, eg at present there are no predictors for primary non-response 
to anti-TNF.   
Synovial biomarkers of mechanistic interest but currently unlikely to be 
broadly useful clinically because few units perform synovial biopsy 
 
 
Remission biomarkers 
• Lack of synovitis on imaging (MSUS, MRI). 
Limitations:   
Requires infrastructure.   
Does not correlate with ability to stop therapy without precipitating flare  
 
 
Tolerance biomarkers 
• None identified in autoimmune disease.   
Gaps 
Essential to develop/monitor tolerogenic therapies 
May also be useful for monitoring disease tapering for patients in 
remission 
Box 2 
 
Current biological therapies for rheumatoid arthritis 
 
TNF antagonists: 
infliximab 
 chimeric monoclonal antibody 
 neutralises TNFα 
 binds soluble and cell surface TNFα 
 administered by intravenous infusion every 8 weeks following 
loading doses 
  
etanercept 
 recombinant dimeric fusion protein of p75 TNF receptor and hinge, 
CH2 ad CH3 of human IgG1 
 neutralises TNFα 
 binds cell surface TNFα with lower affinity than monoclonal 
antibodies 
 administered by weekly subcutaneous injection 
  
adalimumab 
 fully human monoclonal antibody  
 neutralises TNFα 
 binds soluble and cell surface TNFα 
 administered by subcutaneous injection every other week 
  
golimumab 
 fully human monoclonal antibody  
 neutralises TNFα 
 binds soluble and cell surface TNFα 
 administered by monthly subcutaneous injection 
  
certolizumab pegol 
 PEGylated humanised FAB fragment. No Fc. 
 neutralises TNFα 
 binds soluble and cell surface TNFα 
 administered by subcutaneous injection every other week following 
loading dose 
  
  
Anti-B cell therapy  
Rituximab 
 Chimaeric monoclonal antibody  
 Binds to CD20 and lyses CD20-expressing target cells 
 Administered by a course of 2 intravenous infusions, which can be 
repeated according to disease activity (usually approximately every 6 
months) 
  
 
Costimulation blockade 
Abatacept 
 Fusion protein between the extracellular domain of CTLA4 and a 
modified hinge, CH2 and CH3 of human IgG1 
 Binds CD80 and CD86 in competition with CD28, inhibiting T-cell 
activation (costimulation blockade) 
 Administered by monthly intravenous infusion after loading doses 
  
 
Anti-IL6 therapy 
Tocilizumab 
 Humanised monoclonal antibody 
 Binds soluble and cell surface bound IL6 receptor, inhibiting IL-6 
signalling 
 Administered by monthly intravenous infusion 
  
Box 3 
 
Areas of current and future research with potential therapeutic impact 
 
Improved markers of ‘pre-RA’ – early identification of ‘at risk’ individuals, 
enabling ‘preventative’ studies 
Window of opportunity – what is/are the pathological correlates? 
Therapeutic ‘escape’ – what underlies loss of therapeutic response. 
?similar to tumour ‘escape’ in malignancy  
Methotrexate – identification of mode of action and efficacy biomarkers, to 
optimise therapy with this ‘anchor’ drug and develop related compounds 
Biomarkers of diagnosis to enable rapid diagnosis 
Biomarkers of prognosis to assist targeted treatment 
Biomarkers of therapeutic response to optimise choice of therapy 
Biomarkers of true remission (imaging and blood) to assist with therapy 
tapering  
Biomarkers of tolerance induction to inform withdrawal of therapy 
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